circPVT1 Inhibits the Proliferation and Aids in Prediction of the Prognosis of Bladder Cancer

References

• Lobo N, Afferi L, Moschini M, et al. Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol. 2022;5(6):628–639. doi:10.1016/j.euo.2022.10.003
   PubMed Web of Science ®Google Scholar
• Al Saidi I, Mohamedabugroon A, Sawalha A, et al. Epidemiology of bladder cancer in the Arab World: 2019 global burden of disease data. Asian Pac J Cancer Prev. 2022;23(9):2907–2919. doi:10.31557/APJCP.2022.23.9.2907
   PubMedGoogle Scholar
• Xie J, Jiang H, Zhao Y, et al. Prognostic and diagnostic value of circRNA expression in prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:945143. doi:10.3389/fonc.2022.945143
   PubMed Web of Science ®Google Scholar
• Zhu G, Chang X, Kang Y, et al. CircRNA: a novel potential strategy to treat thyroid cancer (Review). Int J Mol Med. 2021;48(5). doi:10.3892/ijmm.2021.5034
   Web of Science ®Google Scholar
• Liang Y, Liu N, Yang L, et al. A brief review of circRNA biogenesis, detection, and function. Curr Genomics. 2021;22(7):485–495. doi:10.2174/1389202922666210331130722
   PubMed Web of Science ®Google Scholar
• Lin Z, Tang X, Wang L, et al. Prognostic and clinicopathological value of circPVT1 in human cancers: a meta-analysis. Cancer Rep. 2021;4(5):e1385. doi:10.1002/cnr2.1385
   Google Scholar
• Ghafouri-Fard S, Khoshbakht T, Taheri M, et al. A concise review on the role of CircPVT1 in tumorigenesis, drug sensitivity, and cancer prognosis. Front Oncol. 2021;11:762960. doi:10.3389/fonc.2021.762960
   PubMed Web of Science ®Google Scholar
• Zhang H, Ren G, Wang X, et al. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases. Breast Cancer Res Treat. 2012;134(2):743–749. doi:10.1007/s10549-012-2101-x
   PubMed Web of Science ®Google Scholar
• Wang L, Wu S, He H, et al. CircRNA-ST6GALNAC6 increases the sensitivity of bladder cancer cells to erastin-induced ferroptosis by regulating the HSPB1/P38 axis. Lab Invest. 2022;102(12):1323–1334. doi:10.1038/s41374-022-00826-3
   PubMed Web of Science ®Google Scholar
• Li G, Guo BY, Wang HD, et al. CircRNA hsa_circ_0014130 function as a miR-132-3p sponge for playing oncogenic roles in bladder cancer via upregulating KCNJ12 expression. Cell Biol Toxicol. 2022;38(6):1079–1096. doi:10.1007/s10565-021-09668-z
   PubMed Web of Science ®Google Scholar
• Peng G, Meng H, Pan H, et al. CircRNA 001418 promoted cell growth and metastasis of bladder carcinoma via EphA2 by miR-1297. Curr Mol Pharmacol. 2021;14(1):68–78. doi:10.2174/1874467213666200505093815
   PubMed Web of Science ®Google Scholar
• Grote I, Bartels S, Christgen H, et al. ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer. Mod Pathol. 2022;35(12):1804–1811. doi:10.1038/s41379-022-01130-7
   PubMed Web of Science ®Google Scholar
• Friedrich RE, Nornberg LKN, Hagel C. ERBB2 and ERBB3 growth factor receptors, neuregulin-1, CD44 and Ki-67 proliferation index in neurofibromatosis type 1-associated peripheral nerve sheath tumors. Anticancer Res. 2022;42(5):2327–2340. doi:10.21873/anticanres.15712
   PubMed Web of Science ®Google Scholar
• Jayaraman S, Pazhani J, Priyaveeraraghavan V, et al. PCNA and Ki67: prognostic proliferation markers for oral cancer. Oral Oncol. 2022;130:105943. doi:10.1016/j.oraloncology.2022.105943
   PubMed Web of Science ®Google Scholar
• Velez MG, Kosiorek HE, Egan JB, et al. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(3):479–483. doi:10.1038/s41391-021-00430-4
   PubMed Web of Science ®Google Scholar
• Shi J, Lv X, Zeng L, et al. CircPVT1 promotes proliferation of lung squamous cell carcinoma by binding to miR-30d/e. J Exp Clin Cancer Res. 2021;40(1):193. doi:10.1186/s13046-021-01976-w
   PubMed Web of Science ®Google Scholar
• Huang M, Li T, Wang Q, et al. Silencing circPVT1 enhances radiosensitivity in non-small cell lung cancer by sponging microRNA-1208. Cancer Biomark. 2021;31(3):263–279. doi:10.3233/CBM-203252
   PubMed Web of Science ®Google Scholar
• Cao L, Zhou X, Ding X, et al. Knockdown of circ‑PVT1 inhibits the progression of lung adenocarcinoma and enhances the sensitivity to cisplatin via the miR‑429/FOXK1 signaling axis. Mol Med Rep. 2021;24(4). doi:10.3892/mmr.2021.12323
   Web of Science ®Google Scholar
• Zheng X, Rui S, Wang XF, et al. circPVT1 regulates medullary thyroid cancer growth and metastasis by targeting miR-455-5p to activate CXCL12/CXCR4 signaling. J Exp Clin Cancer Res. 2021;40(1):157. doi:10.1186/s13046-021-01964-0
   PubMed Web of Science ®Google Scholar
• Zeng L, Yuan S, Zhou P, et al. Circular RNA Pvt1 oncogene (CircPVT1) promotes the progression of papillary thyroid carcinoma by activating the Wnt/beta-catenin signaling pathway and modulating the ratio of microRNA-195 (miR-195) to vascular endothelial growth factor A (VEGFA) expression. Bioengineered. 2021;12(2):11795–11810. doi:10.1080/21655979.2021.2008639
   PubMed Web of Science ®Google Scholar
• Wang S, Su TT, Tong H, et al. CircPVT1 promotes gallbladder cancer growth by sponging miR-339-3p and regulates MCL-1 expression. Cell Death Discov. 2021;7(1):191. doi:10.1038/s41420-021-00577-y
   PubMed Web of Science ®Google Scholar
• Jia Y, Gu W. Up-regulation of circPVT1 in T cell acute lymphoblastic leukemia promoted cell proliferation via miR-30e/DLL4 induced activating NOTCH signaling. Pathol Res Pract. 2021;224:153536. doi:10.1016/j.prp.2021.153536
   PubMed Web of Science ®Google Scholar
• Hao Y, Lu C, Zhang B, et al. CircPVT1 up-regulation attenuates steroid-induced osteonecrosis of the femoral head through regulating miR-21-5p-mediated Smad7/TGFbeta signalling pathway. J Cell Mol Med. 2021;25(10):4608–4622. doi:10.1111/jcmm.16294
   PubMed Web of Science ®Google Scholar
• Claps F, Mir MC, Van Rhijn BWG, et al. Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol. 2023;41(1):49 e13–49 e22. doi:10.1016/j.urolonc.2022.09.023
   PubMed Web of Science ®Google Scholar
• Grossmann NC, Schuettfort VM, Pradere B, et al. Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. Urol Oncol. 2022;40(3):106 e11–e19. doi:10.1016/j.urolonc.2021.10.006
   PubMed Web of Science ®Google Scholar
• Von Deimling M, Schuettfort VM, D’Andrea D, et al. Predictive and prognostic role of the neutrophil-to-lymphocyte ratio in muscle invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Clin Genitourin Cancer. 2023;21(4):430–441. doi:10.1016/j.clgc.2023.01.008
   PubMed Web of Science ®Google Scholar
• Claps F, Mir MC, Zargar H. Molecular markers of systemic therapy response in urothelial carcinoma. Asian J Urol. 2021;8(4):376–390. doi:10.1016/j.ajur.2021.05.001
   PubMed Web of Science ®Google Scholar
• Mir MC, Campi R, Loriot Y, et al. Adjuvant systemic therapy for high-risk muscle-invasive bladder cancer after radical cystectomy: current options and future opportunities. Eur Urol Oncol. 2022;5(6):726–731. doi:10.1016/j.euo.2021.04.004
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Blanca A, Cimadamore A, et al. T1 bladder carcinoma with variant histology: pathological features and clinical significance. Virchows Arch. 2022;480(5):989–998. doi:10.1007/s00428-021-03264-6
   PubMed Web of Science ®Google Scholar
• Claps F, Van De Kamp MW, Mayr R, et al. Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. BJU Int. 2023;132(2):170–180. doi:10.1111/bju.15984
   PubMed Web of Science ®Google Scholar